Pipoxolan (hydrochloride)

Pipoxolan hydrochloride is an anti-spasmotic agent. Pipoxolan hydrochloride induces Apoptosis, increases intracellular ROS. Pipoxolan hydrochloride down-regulates phosphorylation JNK and p38, and then, MMP-2 and -9. Pipoxolan hydrochloride relieves smooth muscle spasms in the digestive, urinary, and gynecological systems. Pipoxolan hydrochloride also exhibits anticancer activity against leukemia, oral squamous cell carcinoma, and lung adenocarcinoma[1][2][3][4].

Product Specifications

CAS Number

[18174-58-8]

UNSPSC

12352005

Target

Apoptosis; JNK; MMP; p38 MAPK; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

Field of Research

Cancer

Smiles

O=C1OC(CCN2CCCCC2)OC1(C3=CC=CC=C3)C4=CC=CC=C4.Cl

Molecular Formula

C22H26ClNO3

Molecular Weight

387.90

References & Citations

[1]Sheu MJ, et al. Pipoxolan inhibits proliferation of HL-60 human leukaemia cancer cells by arresting the cell cycle at the G0/G1 phase. Clin Exp Pharmacol Physiol. 2010 May;37 (5-6) :605-12. |[2]Chou PY, et al. Pipoxolan Exhibits Antitumor Activity Toward Oral Squamous Cell Carcinoma Through Reactive Oxygen Species-mediated Apoptosis. Anticancer Res. 2017 Nov;37 (11) :6391-6400. |[3]Lee MM, et al. Pipoxolan inhibits CL1-5 lung cancer cells migration and invasion through inhibition of MMP-9 and MMP-2. Chem Biol Interact. 2015 Jul 5;236:19-30. |[4]Chen Y, et al. Novel anti-leukemia activities of pipoxolan operate via the mitochondria-related pathway in human leukemia U937 cells and attenuate U937 cell growth in an animal model. Mol Med Rep. 2010 Sep-Oct;3 (5) :851-6.